Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Danilo De Gregorio(University of Campania "Luigi Vanvitelli"), Gabriella Gobbi(McGill University), Argel Aguilar‐Valles(Carleton University), Meghan Hibicke(Louisiana State University Health Sciences Center New Orleans), Katrin H. Preller(University of Zurich), Boris D. Heifets(Stanford Medicine), Jennifer Mitchell(The University of Texas MD Anderson Cancer Center)
Cited by 258
Related Papers
Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood
|JAMA Psychiatry|2019|911
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis
|Proceedings of the National Academy of Sciences|2005|677
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
|Pharmacological Reviews|2018|386
Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype
|Nature Neuroscience|2006|373